Literature DB >> 24793301

Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications.

Shen Yin1, Colleen M Niswender2.   

Abstract

The metabotropic glutamate (mGlu) receptors are a group of Class C seven-transmembrane spanning/G protein-coupled receptors (7TMRs/GPCRs). These receptors are activated by glutamate, one of the standard amino acids and the major excitatory neurotransmitter. By activating G protein-dependent and non-G protein-dependent signaling pathways, mGlus modulate glutamatergic transmission both in the periphery and throughout the central nervous system. Since the discovery of the first mGlu receptor, and especially during the last decade, a great deal of progress has been made in understanding the signaling, structure, pharmacological manipulation and therapeutic indications of the 8 mGlu members.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  7TMR; Allosteric modulation; Drug discovery; Heterodimer; Pharmacology; mGlu

Mesh:

Substances:

Year:  2014        PMID: 24793301      PMCID: PMC4130774          DOI: 10.1016/j.cellsig.2014.04.022

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  246 in total

1.  Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+.

Authors:  Daisuke Tsuchiya; Naoki Kunishima; Narutoshi Kamiya; Hisato Jingami; Kosuke Morikawa
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

2.  Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator.

Authors:  Huixian Wu; Chong Wang; Karen J Gregory; Gye Won Han; Hyekyung P Cho; Yan Xia; Colleen M Niswender; Vsevolod Katritch; Jens Meiler; Vadim Cherezov; P Jeffrey Conn; Raymond C Stevens
Journal:  Science       Date:  2014-03-06       Impact factor: 47.728

3.  Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM.

Authors:  Douglas J Sheffler; Cody J Wenthur; Joshua A Bruner; Sheridan J S Carrington; Paige N Vinson; Kiran K Gogi; Anna L Blobaum; Ryan D Morrison; Mitchell Vamos; Nicholas D P Cosford; Shaun R Stauffer; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2012-04-30       Impact factor: 2.823

4.  Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study.

Authors:  J C Pecknold; D J McClure; L Appeltauer; L Wrzesinski; T Allan
Journal:  J Clin Psychopharmacol       Date:  1982-04       Impact factor: 3.153

5.  The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.

Authors:  J Cartmell; J A Monn; D D Schoepp
Journal:  J Pharmacol Exp Ther       Date:  1999-10       Impact factor: 4.030

6.  Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective.

Authors:  Filippo Caraci; Gemma Molinaro; Giuseppe Battaglia; Maria Laura Giuffrida; Barbara Riozzi; Anna Traficante; Valeria Bruno; Milena Cannella; Sara Merlo; Xushan Wang; Beverly A Heinz; Eric S Nisenbaum; Thomas C Britton; Filippo Drago; Maria Angela Sortino; Agata Copani; Ferdinando Nicoletti
Journal:  Mol Pharmacol       Date:  2010-12-15       Impact factor: 4.436

7.  Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence.

Authors:  Matthias E Liechti; Loic Lhuillier; Klemens Kaupmann; Athina Markou
Journal:  J Neurosci       Date:  2007-08-22       Impact factor: 6.167

8.  Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site.

Authors:  Blake A Rowe; Hervé Schaffhauser; Sylvia Morales; Laura S Lubbers; Celine Bonnefous; Theodore M Kamenecka; Jeffrey McQuiston; Lorrie P Daggett
Journal:  J Pharmacol Exp Ther       Date:  2008-04-22       Impact factor: 4.030

9.  Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor.

Authors:  Pari Malherbe; Nicole Kratochwil; Frédéric Knoflach; Marie-Thérèse Zenner; James N C Kew; Claudia Kratzeisen; Hans P Maerki; Geo Adam; Vincent Mutel
Journal:  J Biol Chem       Date:  2002-12-30       Impact factor: 5.157

10.  Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways.

Authors:  L Iacovelli; V Bruno; L Salvatore; D Melchiorri; R Gradini; A Caricasole; E Barletta; A De Blasi; F Nicoletti
Journal:  J Neurochem       Date:  2002-07       Impact factor: 5.372

View more
  22 in total

1.  Alteration by p11 of mGluR5 localization regulates depression-like behaviors.

Authors:  K-W Lee; L Westin; J Kim; J C Chang; Y-S Oh; B Amreen; J Gresack; M Flajolet; D Kim; A Aperia; Y Kim; P Greengard
Journal:  Mol Psychiatry       Date:  2015-09-15       Impact factor: 15.992

2.  Expression of mGlu Receptor Genes in the Hippocampus After Intoxication with Trimethyltin.

Authors:  E V Pershina; I B Mikheeva; E R Kamaltdinova; V I Arkhipov
Journal:  J Mol Neurosci       Date:  2018-11-30       Impact factor: 3.444

3.  Metabotropic Glutamate Receptors in Alcohol Use Disorder: Physiology, Plasticity, and Promising Pharmacotherapies.

Authors:  Max E Joffe; Samuel W Centanni; Anel A Jaramillo; Danny G Winder; P Jeffrey Conn
Journal:  ACS Chem Neurosci       Date:  2018-06-08       Impact factor: 4.418

Review 4.  Location-dependent signaling of the group 1 metabotropic glutamate receptor mGlu5.

Authors:  Yuh-Jiin I Jong; Ismail Sergin; Carolyn A Purgert; Karen L O'Malley
Journal:  Mol Pharmacol       Date:  2014-10-17       Impact factor: 4.436

5.  Postsynaptic mGluR5 promotes evoked AMPAR-mediated synaptic transmission onto neocortical layer 2/3 pyramidal neurons during development.

Authors:  Kristofer W Loerwald; Ankur B Patel; Kimberly M Huber; Jay R Gibson
Journal:  J Neurophysiol       Date:  2014-11-12       Impact factor: 2.714

Review 6.  Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment.

Authors:  Amr Ellaithy; Jason Younkin; Javier González-Maeso; Diomedes E Logothetis
Journal:  Trends Neurosci       Date:  2015-07-04       Impact factor: 13.837

7.  Amygdala group II mGluRs mediate the inhibitory effects of systemic group II mGluR activation on behavior and spinal neurons in a rat model of arthritis pain.

Authors:  Mariacristina Mazzitelli; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2019-07-12       Impact factor: 5.250

8.  Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system.

Authors:  Luisa Di Menna; Max E Joffe; Luisa Iacovelli; Rosamaria Orlando; Craig W Lindsley; Jèrome Mairesse; Pierre Gressèns; Milena Cannella; Filippo Caraci; Agata Copani; Valeria Bruno; Giuseppe Battaglia; P Jeffrey Conn; Ferdinando Nicoletti
Journal:  Neuropharmacology       Date:  2017-10-25       Impact factor: 5.250

Review 9.  Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies.

Authors:  Irina Esterlis; Sophie E Holmes; Priya Sharma; John H Krystal; Christine DeLorenzo
Journal:  Biol Psychiatry       Date:  2017-09-19       Impact factor: 13.382

10.  Immuno-pharmacological characterization of group II metabotropic glutamate receptors controlling glutamate exocytosis in mouse cortex and spinal cord.

Authors:  Guendalina Olivero; Tommaso Bonfiglio; Matteo Vergassola; Cesare Usai; Barbara Riozzi; Giuseppe Battaglia; Ferdinando Nicoletti; Anna Pittaluga
Journal:  Br J Pharmacol       Date:  2017-10-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.